IAVI recommends new business models for increasing access to monoclonal antibodies

Together with partners Unitaid, the Medicines Patent Pool, and Wellcome, IAVI has released a set of new recommendations for improving access to monoclonal antibodies (mAbs) in low-income countries. Monoclonal antibodies are used today to treat cancers, autoimmune disorders, and are currently being explored as a new preventive and treatment tool for infectious diseases. Access to mAbs in low-income country contexts is extremely limited, and new approaches are needed to ensure access.

Read more about the new business approaches that can advance mAb access.